Parameters (n = 30) | Number of patients (%) |
---|---|
Age (years old) | 62 (31–80) |
Degree of progress | |
 Locally advanced/visceral metastases | 10 (33.3%)/20 (66.7%) |
Stage | |
 Stage IIIC/stage IV/recurrence | 4 (13.3%)/11 (36.7%)/15 (50.0%) |
Site of metastases | |
 Lung/bone/liver/brain/lymph node/soft tissue | 11 (36.7%)/12 (40.0%)/7 (23.3%)/3 (10.0%)/12 (40.0%)/11 (36.6%) |
Treatment line | |
 First/other | 17 (56.7%)/13 (43.3%) |
ER | |
 Negative/positive | 18 (60.0%)/12 (40.0%) |
PgR | |
 Negative/positive | 20 (66.7%)/10 (33.3%) |
Ki67 | |
 Negative/positive | 16 (55.2%)/14 (44.8%) |
CD8 | |
 Negative/positive | 21 (70.0%)/9 (30.0%) |
FOXP3 | |
 Negative/positive | 15 (50.0%)/15 (50.0%) |
CFR | |
 Low/high | 15 (50.0%)/15 (50.0%) |
PD1 | |
 Negative/positive | 14 (46.7%)/16 (53.3%) |
PD-L1 | |
 Negative/positive | 19 (63.3%)/11 (36.7%) |
CD163 | |
 Negative/positive | 15 (50.0%)/15 (50.0%) |
PTEN | |
 Negative/positive | 17 (56.7%)/13 (43.3%) |
LAG3 | |
 Negative/positive | 20 (66.7%)/10 (33.3%) |